Following temporary bans on elective procedures earlier this year due to the COVID-19 pandemic, Guidepoint Qsight was able to capture the effects on aesthetics volumes.
Following the sharp declines in March-May, Breast Implant procedures resumed with a tremendous amount of backlog and rebounded back to pre-COVID-19 levels in June 2020 and even accelerating to a growth of nearly 15% at the end of September 2020, defying traditional seasonal trends.
Dermal fillers and neurotoxins also seemed to be on a track to recovery, however, total U.S. aesthetic injection volumes were down year-over-year by approximately 15% in September 2020.
The question remains if Breast Implant procedures will continue to hold this level of growth and if the decline in dermal fillers and neurotoxin injections will continue long term.
The above is based on primary survey data gathered from a proprietary panel of physicians from 130+ unique healthcare sites performing aesthetics procedures on a monthly longitudinal basis. To learn more about Qsight’s insight into recent aesthetics trends, check out the Medical Aesthetics TRACKER Alert – October 2020.
Post created by: Shimul Sheth, Quantitative Analyst, Guidepoint Qsight & Sean Sookhoo, Senior Healthcare Analyst, Guidepoint Qsight